Following U.S. Stocks were among the “Top Gainers” during Monday’s trade: Constellation Brands, Inc (NYSE:STZ), Xenia Hotels & Resorts, Inc (NYSE:XHR), Molycorp Inc (NYSE:MCP), CEL-SCI Corporation (NYSEMKT:CVM)

Their insights are depicted underneath:

Constellation Brands, Inc (NYSE:STZ)’s shares picked up 3.90%, and closed at $115.23. The company holds the market capitalization of 22.05B. The stock return on equity value is 14.60%, while return on assets value is 5.30%, in response to its return on investment value of 18.20%. Its 20-day moving average gained 0.84%, and the stock moved above 50-day moving average of 4.79%. The mean recommendation of analysts for this stock is 2.30.(where 1=Buy, 5=Sale).

Constellation Brands, Inc., together with its auxiliaries, produces, imports, and markets beer, wine, and spirits in the United States, Canada, Mexico, New Zealand, and Italy.

Xenia Hotels & Resorts, Inc (NYSE:XHR), raised 3.88%, and closed at $21.97.

Through PRNewswire, Xenia Hotels & Resorts, Inc. (XHR), declared the final results and settlement of its formerly declared modified “Dutch Auction” self-tender offer (the “Tender Offer”) to purchase for cash up to $125 million in value of shares of the Corporation’s ordinary stock, which expired at 5:00 p.m., New York City Time, on March 5, 2015.

The Corporation has accepted for purchase 1,784,401 shares of its ordinary stock at a purchase price of $21.00 per share, for an aggregate purchase price of about $37.5 million (not including fees and expenses regarding the Tender Offer), which was funded from cash on hand. Payment for the shares of ordinary stock accepted for purchase occurred on March 9, 2015, and the shares of ordinary stock purchased were automatically stepped down. DST Systems, Inc., the depositary for the Tender Offer, will issue payment for the shares of ordinary stock validly tendered and accepted for purchase in accordance with the terms and conditions of the Tender Offer.

Stockholders who properly tendered and did not properly withdraw shares of ordinary stock in the Tender Offer at or below the final purchase price of $21.00 per share had all of their tendered shares purchased by the Corporation. The 1,784,401 shares of ordinary stock purchased in the Tender Offer represent about 1.6% of the Corporation’s ordinary stock outstanding as of February 3, 2015, the last day preceding to the commencement of the Tender Offer. The Corporation had about 111,639,584 shares of ordinary stock outstanding right away following payment for the shares of ordinary stock purchased in the Tender Offer.

Xenia Hotels & Resorts, Inc. is a self-advised and self-administered REIT that invests primarily in premium full service, lifestyle and urban upscale hotels, with a focus on the top 25 U.S. lodging markets in addition to key leisure destinations in the United States.

Molycorp Inc (NYSE:MCP), enhanced 3.88%, and closed at $0.855.The company holds the book value per share of 4.91, whereas cash per share is 1.28. Price to book value is estimated to be 0.17, while price to sale value is 0.43. Analysts mean recommendation for the stock is said to be 3.70 (where 1=Buy, 5=sale).

Molycorp, Inc. produces and sells rare earths and rare metal materials in the United States and internationally. The corporation’s Resources segment extracts rare earth minerals, counting light rare earth concentrates; rare earth oxides (REO), such as lanthanum, cerium, and neodymium/praseodymium; heavy rare earth concentrates, which comprise samarium, europium, gadolinium, terbium, dysprosium, and others; and SorbX, a line of rare earth-based water treatment products.

CEL-SCI Corporation (NYSEMKT:CVM), rose 3.77%, and closed at $1.10.

CEL-SCI Corporation (CVM), declared that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This follows January’s preceding record. A total of 377 patients have been enrolled in the world’s largest Phase III study in head and neck cancer as of February 28, 2015.

The aim is to enroll a total of 880 patients through about 100 clinical centers in about 25 countries by the end of 2015.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. The corporation’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer.